Clinical trial
When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)
NCT00234091 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00234091 |
|---|---|
| Title | When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study) |
| Official title | An Open Label, Randomized Study to Compare Antiretroviral Therapy (ART) Initiation When CD4 is Between 15% to 24% to ART Initiation When CD4 Falls Below 15% in Children With HIV Infection and Moderate Immune Suppression |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Comprehensive International Program of Research on AIDS |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Abacavir, Efavirenz, Lamivudine, Lopinavir/Ritonavir, Nelfinavir, Nevirapine, Zidovudine |
| Enrollment | 300 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Oct 6, 2005 |
| Last update posted | Dec 4, 2013 |
| Countries | Cambodia, Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: